Results 151 to 160 of about 41,151 (199)
Continuous Dopaminergic Stimulation-Based Levodopa Treatment in Patients with Early to Mid-Stage Parkinson's Disease: A Systematic Review and Meta-Analysis. [PDF]
Neurol TherTang R +6 more
europepmc +1 more source
Drug-Induced Parkinsonism or Parkinson's Disease: A Diagnostic Challenge in a Psychiatric Patient. [PDF]
CureusBalcerzak W +4 more
europepmc +1 more source
Sublingual Crushed Levodopa for Parkinson's Disease Management of a Lewy Body Dementia Patient With Dysphagia: A Case Report. [PDF]
CureusRegehr K, Yu J, Wu F, Shah R, Lau A.
europepmc +1 more source
Approaches for treating cardiovascular symptoms in Parkinson's disease. [PDF]
Ther Adv Neurol DisordJost WH, Koschel J.
europepmc +1 more source
Use of safinamide for treatment of Parkinson disease: real-world data from Spain. [PDF]
Drugs ContextMorales Casado MI, López Ariztegui N.
europepmc +1 more source
Some of the next articles are maybe not open access.
Related searches:
Related searches:
JAMA: The Journal of the American Medical Association, 1970
To the Editor.— The use of levodopa (L-DOPA; dihydroxyphenylalanine) for the treatment of Parkinson's disease has been satisfactorily demonstrated in many cases when other therapeutic measures fail to act. It has been reported in the available literature 1,2 that the administration of levodopa might cause psychiatric symptoms (eg, hallucinations ...
Sidney Merlis, Jose A. Yaryura Tobias
openaire +3 more sources
To the Editor.— The use of levodopa (L-DOPA; dihydroxyphenylalanine) for the treatment of Parkinson's disease has been satisfactorily demonstrated in many cases when other therapeutic measures fail to act. It has been reported in the available literature 1,2 that the administration of levodopa might cause psychiatric symptoms (eg, hallucinations ...
Sidney Merlis, Jose A. Yaryura Tobias
openaire +3 more sources
Journal of Neurology, 2004
The objective of this workshop was to review and discuss the debate on neurotoxicity of levodopa in the treatment of Parkinson's disease (PD) with consideration of preclinical and clinical findings. We concluded that in particular preclinical outcomes of in vitro models of neurodegeneration describe neurotoxic effects of levodopa, whereas trials in ...
Johannes Schwarz +6 more
openaire +4 more sources
The objective of this workshop was to review and discuss the debate on neurotoxicity of levodopa in the treatment of Parkinson's disease (PD) with consideration of preclinical and clinical findings. We concluded that in particular preclinical outcomes of in vitro models of neurodegeneration describe neurotoxic effects of levodopa, whereas trials in ...
Johannes Schwarz +6 more
openaire +4 more sources
Clinical Pharmacology & Therapeutics, 1971
Based on the chemical constitution and metabolism of levodopa as well as on the effects of long‐term therapy in patients with parkinsonism, a hypothesis of pharmacologic activity which clearly differentiates it from conventional antiparkinsonian drugs is proposed.
Simone E. Düby +3 more
openaire +3 more sources
Based on the chemical constitution and metabolism of levodopa as well as on the effects of long‐term therapy in patients with parkinsonism, a hypothesis of pharmacologic activity which clearly differentiates it from conventional antiparkinsonian drugs is proposed.
Simone E. Düby +3 more
openaire +3 more sources